Phase 2 Marginal Zone Lymphoma Clinical Trials
38 recruitingPhase 2
What is a Phase 2 trial?
Phase 2 trials evaluate whether a treatment works for a specific condition and further assess its safety. These studies typically enroll several hundred participants and provide preliminary data on effectiveness.
Showing 1–20 of 38 trials
Recruiting
Phase 1Phase 2
A Dose-Escalation and Expansion Study of BGB-16673 in Participants With B-Cell Malignancies
Diffuse Large B Cell LymphomaChronic Lymphocytic LeukemiaNon-Hodgkin Lymphoma+6 more
BeOne Medicines645 enrolled130 locationsNCT05006716
Recruiting
Phase 2
Donor Stem Cell Transplant With Treosulfan, Fludarabine, and Total-Body Irradiation for the Treatment of Hematological Malignancies
Acute Lymphoblastic LeukemiaAcute Myeloid LeukemiaHodgkin Lymphoma+16 more
Fred Hutchinson Cancer Center60 enrolled1 locationNCT04195633
Recruiting
Phase 1Phase 2
Treatment of Chinese Participants With B-Cell Malignancies With BGB-16673, a Bruton Tyrosine Kinase-Targeted Protein-Degrader
Non-Hodgkin LymphomaMantle Cell LymphomaFollicular Lymphoma+6 more
BeiGene146 enrolled29 locationsNCT05294731
Recruiting
Phase 1Phase 2
Autologous Stem Cell Transplant Followed by Polatuzumab Vedotin in Patients With B-cell Non-Hodgkin and Hodgkin Lymphoma
Diffuse Large B Cell LymphomaHodgkin LymphomaMantle Cell Lymphoma+6 more
New York Medical College20 enrolled1 locationNCT04491370
Recruiting
Phase 1Phase 2
Gene Therapy for CD19-Positive Hematologic Malignancies (SENTRY-CD19)
Diffuse Large B Cell LymphomaHigh-grade B-cell LymphomaChronic Lymphocytic Leukemia+10 more
Vironexis Biotherapeutics Inc.32 enrolled9 locationsNCT06533579
Recruiting
Phase 2
MZL-IPI Risk-adapted Targeted Therapy in Untreated MZL
Marginal Zone Lymphoma (MZL)
Ruijin Hospital145 enrolled3 locationsNCT06793189
Recruiting
Phase 2
Rituximab Plus Venetoclax in Front Line Marginal Zone Lymphoma
LymphomaMarginal Zone LymphomaMZL
Gottfried von Keudell, MD PhD33 enrolled1 locationNCT06510309
Recruiting
Phase 2
Low Dose Mosunetuzumab for the Treatment of Patients With Indolent B-Cell Lymphoma
Ann Arbor Stage II Follicular LymphomaGrade 1 Follicular LymphomaAnn Arbor Stage III Follicular Lymphoma+6 more
University of Washington20 enrolled1 locationNCT06442475
Recruiting
Phase 2
Orelabrutinib Combined With Rituximab ± Lenalidomide in Response-Adapted Stratified Therapy for Untreated MZL
Marginal Zone Lymphoma (MZL)
The First Affiliated Hospital with Nanjing Medical University50 enrolled1 locationNCT07448324
Recruiting
Phase 2
Exploratory Study of Orelabrutinib in the Treatment of Early-stage Untreated MZL
Marginal Zone Lymphoma
Institute of Hematology & Blood Diseases Hospital, China30 enrolled14 locationsNCT07441993
Recruiting
Phase 2
Optimize Study - Orelabrutinib Combined With BR/G in Untreated Marginal Zone Lymphoma (MZL)
Marginal Zone Lymphoma
First Affiliated Hospital of Zhejiang University69 enrolled1 locationNCT06504940
Recruiting
Phase 1Phase 2
CAR-20/19-T Cells in Patients With Relapsed Refractory B Cell Malignancies
Diffuse Large B Cell LymphomaFollicular LymphomaMarginal Zone Lymphoma+5 more
Medical College of Wisconsin100 enrolled1 locationNCT04186520
Recruiting
Phase 2
Epco, Zanu, Ritux for R/R FL or MZL
Non-Hodgkin LymphomaLymphomaFollicular Lymphoma+3 more
Reid Merryman, MD45 enrolled3 locationsNCT06563596
Recruiting
Phase 2
Acalabrutinib and Obinutuzumab for the Treatment of Previously Untreated Follicular Lymphoma or Other Indolent Non-Hodgkin Lymphomas
Mantle Cell LymphomaLymphoproliferative DisorderMarginal Zone Lymphoma+5 more
Emory University49 enrolled1 locationNCT04883437
Recruiting
Phase 2
Rituximab and Zanubrutinib in Patients With Indolent B-cell Lymphomas
Follicular LymphomaMarginal Zone LymphomaB-cell Lymphoma
H. Lee Moffitt Cancer Center and Research Institute43 enrolled1 locationNCT06350318
Recruiting
Phase 1Phase 2
A Novel Vaccine (EO2463) as Monotherapy and in Combination, for Treatment of Patients With Indolent Non-Hodgkin Lymphoma
Follicular LymphomaMarginal Zone Lymphoma
Enterome80 enrolled12 locationsNCT04669171
Recruiting
Phase 2
Orelabrutinib as Consolidation and Maintenance Therapy in Treatment-Naïve MZL.
Marginal Zone Lymphoma (MZL)
The First Affiliated Hospital of Soochow University23 enrolled1 locationNCT07372365
Recruiting
Phase 2
Mosunetuzumab With Lenalidomide Augmentation as First-line Therapy for Follicular and Marginal Zone Lymphoma
Follicular LymphomaMarginal Zone LymphomaB-cell Lymphoma
Brown University52 enrolled3 locationsNCT04792502
Recruiting
Phase 2
Pirtobrutinib in Combination With Rituximab in Adults With Untreated Marginal Zone Lymphoma (PIONEER-MZL)
Marginal Zone Lymphoma
University of Utah23 enrolled2 locationsNCT06390956
Recruiting
Phase 2
Pemigatinib in Patients With Relapsed or Refractory B-cell Non-Hodgkin Lymphomas
Mantle Cell LymphomaMarginal Zone LymphomaRelapsed or Refractory B-cell Non-Hodgkin Lymphoma
University of Utah27 enrolled1 locationNCT06300528